Nascent Biotech Inc.
Nascent Biotech Inc. (NBIO): 6 pipeline candidates · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.9 months
D/E -1.44 · 0% dilution
Lead: Approved
6 candidates
N/A
N/A
A transparent, data-derived signal for Nascent Biotech Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$69K
Cash
$47K
Quarterly Burn
$325K
Runway
0.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| buprenorphine | Approved |
| covid-19 vaccine | Preclinical |
| guanfacine | Approved |
| oxycodone | Approved |
| pritumumab | Phase 1 |
| sodium oxybate | Approved |
Frequently asked questions
How many drug candidates are in Nascent Biotech Inc.'s pipeline?
Nascent Biotech Inc. (NBIO) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Nascent Biotech Inc.'s lead drug candidate?
Nascent Biotech Inc.'s most advanced tracked candidate is buprenorphine (Approved) for 1 INDICATIONS AND USAGE Buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. Buprenorphine and naloxone sublingual tablets contains buprenorphine, a partial opioid agonist, and naloxone, an opioid antagonist, and is indicated for the maintenance treatment of opioid dependence. (1) Buprenorphine.
What is Nascent Biotech Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Nascent Biotech Inc. has approximately 0.9 months of cash runway.
What is Nascent Biotech Inc.'s market capitalization?
Nascent Biotech Inc.'s market capitalization is approximately $69K.
Who is the CEO of Nascent Biotech Inc.?
Mr. Sean Carrick is the chief executive officer of Nascent Biotech Inc. (NBIO).
Get the full picture on Nascent Biotech Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.